Korean J Ophthalmol.  2019 Feb;33(1):95-96. 10.3341/kjo.2018.0113.

Nasolacrimal Duct Stenosis after Oral Capecitabine Administration

• Jang Y
• Kim N
• Lee KW
• Choung HK
• Khwarg SI

• KMID: 2434310
• DOI: http://doi.org/10.3341/kjo.2018.0113

Abstract

No abstract available.

MeSH Terms

Capecitabine*
Constriction, Pathologic*
Nasolacrimal Duct*
Capecitabine

Figure

• 

  Fig. 1 (A) Dacryocystographic image of the patient in case 1 revealed focal stenosis of the distal nasolacrimal duct and mild dilatation of the nasolacrimal duct proximal to the stenotic site. Contrast media injected through the right and left lower puncta refluxed through the upper puncta. (B) Dacryocystographic image of the patient in case 2 demonstrated that the right and left nasolacrimal ducts were narrow and irregular. Contrast media injected through the lower puncta in both eyes almost passed to the nasal cavity. Informed consent was received from the patient.

Reference

1. Mansur C, Pfeiffer ML, Esmaeli B. Evaluation and management of chemotherapy-induced epiphora, punctal and canalicular stenosis, and nasolacrimal duct obstruction. Ophthalmic Plast Reconstr Surg. 2017; 33:9–12.

2. Sasaki T, Miyashita H, Miyanaga T, et al. Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug. Jpn J Ophthalmol. 2012; 56:214–218.

3. Noguchi Y, Mitani T, Kawara H, et al. A case of lacrimal duct obstruction caused by capecitabine. Gan To Kagaku Ryoho. 2015; 42:123–125.

4. Eiseman AS, Flanagan JC, Brooks AB, et al. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthalmic Plast Reconstr Surg. 2003; 19:216–224.

5. Prasad S, Kamath GG, Phillips RP. Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy. Acta Ophthalmol Scand. 2000; 78:110–113.